Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms

English version České info

Fungal biofilms are a major cause of human mortality and are recalcitrant to most treatments due to intrinsic drug resistance. These complex communities of multiple cell types form on indwelling medical devices and their eradication often requires surgical removal of infected devices. Here we implicate the molecular chaperone Hsp90 as a key regulator of biofilm dispersion and drug resistance. We previously established that in the leading human fungal pathogen, Candida albicans, Hsp90 enables the emergence and maintenance of drug resistance in planktonic conditions by stabilizing the protein phosphatase calcineurin and MAPK Mkc1. Hsp90 also regulates temperature-dependent C. albicans morphogenesis through repression of cAMP-PKA signalling. Here we demonstrate that genetic depletion of Hsp90 reduced C. albicans biofilm growth and maturation in vitro and impaired dispersal of biofilm cells. Further, compromising Hsp90 function in vitro abrogated resistance of C. albicans biofilms to the most widely deployed class of antifungal drugs, the azoles. Depletion of Hsp90 led to reduction of calcineurin and Mkc1 in planktonic but not biofilm conditions, suggesting that Hsp90 regulates drug resistance through different mechanisms in these distinct cellular states. Reduction of Hsp90 levels led to a marked decrease in matrix glucan levels, providing a compelling mechanism through which Hsp90 might regulate biofilm azole resistance. Impairment of Hsp90 function genetically or pharmacologically transformed fluconazole from ineffectual to highly effective in eradicating biofilms in a rat venous catheter infection model. Finally, inhibition of Hsp90 reduced resistance of biofilms of the most lethal mould, Aspergillus fumigatus, to the newest class of antifungals to reach the clinic, the echinocandins. Thus, we establish a novel mechanism regulating biofilm drug resistance and dispersion and that targeting Hsp90 provides a much-needed strategy for improving clinical outcome in the treatment of biofilm infections.

Vyšlo v časopise: Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms. PLoS Pathog 7(9): e32767. doi:10.1371/journal.ppat.1002257
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002257

Souhrn

Zdroje

1. CowenLESteinbachWJ 2008 Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 7 747 764

2. PfallerMADiekemaDJ 2010 Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36 1 53

3. McNeilMMNashSLHajjehRAPhelanMAConnLA 2001 Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 33 641 647

4. ZaoutisTEArgonJChuJBerlinJAWalshTJ 2005 The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41 1232 1239

5. PfallerMADiekemaDJ 2007 Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20 133 163

6. WilsonLSReyesCMStolpmanMSpeckmanJAllenK 2002 The direct cost and incidence of systemic fungal infections. Value Health 5 26 34

7. LinSJSchranzJTeutschSM 2001 Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 358 366

8. LupettiADanesiRCampaMDel TaccaMKellyS 2002 Molecular basis of resistance to azole antifungals. Trends Mol Med 8 76 81

9. Ostrosky-ZeichnerLCasadevallAGalgianiJNOddsFCRexJH 2010 An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9 719 727

10. AndersonJB 2005 Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3 547 556

11. CowenLE 2008 The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 6 187 198

12. PereaSLopez-RibotJLKirkpatrickWRMcAteeRKSantillanRA 2001 Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45 2676 2684

13. ShapiroRSRobbinsNCowenLE 2011 Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75 213 267

14. BalashovSVParkSPerlinDS 2006 Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50 2058 2063

15. ParkSKellyRKahnJNRoblesJHsuMJ 2005 Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49 3264 3273

16. FinkelJSMitchellAP 2011 Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9 109 118

17. RamageGMowatEJonesBWilliamsCLopez-RibotJ 2009 Our current understanding of fungal biofilms. Crit Rev Microbiol 35 340 355

18. BlankenshipJRMitchellAP 2006 How to build a biofilm: a fungal perspective. Curr Opin Microbiol 9 588 594

19. d'EnfertC 2006 Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr Drug Targets 7 465 470

20. NobileCJMitchellAP 2006 Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 8 1382 1391

21. RamageGMartinezJPLopez-RibotJL 2006 Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 6 979 986

22. KojicEMDarouicheRO 2004 Candida infections of medical devices. Clin Microbiol Rev 17 255 267

23. ViudesAPemanJCantonEUbedaPLopez-RibotJL 2002 Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21 767 774

24. SeidlerMJSalvenmoserSMüllerF-MC 2008 Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother 52 4130 4136

25. PerumalPMekalaSChaffinWL 2007 Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother 51 2454 2463

26. RamageGBachmannSPattersonTFWickesBLLopez-RibotJL 2002 Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 49 973 980

27. MukherjeePKChandraJKuhnDMGhannoumMA 2003 Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 71 4333 4340

28. NettJLincolnLMarchilloKMasseyRHoloydaK 2007 Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 51 510 520

29. NettJESanchezHCainMTAndesDR 2010 Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 202 171 175

30. KumamotoCA 2005 A contact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc Natl Acad Sci U S A 102 5576 5581

31. UppuluriPNettJHeitmanJAndesD 2008 Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52 1127 1132

32. TaipaleMJaroszDFLindquistS 2010 HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11 515 528

33. PearlLHProdromouC 2006 Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75 271 294

34. CowenLESinghSDKöhlerJRCollinsCZaasAK 2009 Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 106 2818 2823

35. PallaviRRoyNNageshanRKTalukdarPPavithraSR 2010 Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem 285 37964 37975

36. ShahinasDLiangMDattiAPillaiDR 2010 A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem 53 3552 3557

37. CowenLELindquistS 2005 Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309 2185 2189

38. SinghSDRobbinsNZaasAKSchellWAPerfectJR 2009 Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 5 e1000532

39. LaFayetteSLCollinsCZaasAKSchellWSBetancourt-QuirozM 2010 PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog 6 e1001069

40. NobleSMFrenchSKohnLAChenVJohnsonAD 2010 Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat Genet 42 590 598

41. ShapiroRSUppuluriPZaasAKCollinsCSennH 2009 Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr Biol 19 621 629

42. RamageGVandeWalleKLopez-RibotJLWickesBL 2002 The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 214 95 100

43. RamageGVande WalleKWickesBLLopez-RibotJL 2001 Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45 2475 2479

44. AndesDNettJOschelPAlbrechtRMarchilloK 2004 Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 72 6023 6031

45. UppuluriPPierceCGThomasDPBubeckSSSavilleSP 2010 The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell 9 1531 1537

46. UppuluriPChaturvediAKSrinivasanABanerjeeMRamasubramaniamAK 2010 Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 6 e1000828

47. UppuluriPChaturvediAKLopez-RibotJL 2009 Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia 168 101 109

48. UppuluriPLopez-RibotJL 2011 An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence 1 483 487

49. CowenLECarpenterAEMatangkasombutOFinkGRLindquistS 2006 Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell 5 2184 2188

50. YoungJCMoarefiIHartlFU 2001 Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154 267 273

51. Garcia-SanchezSAubertSIraquiIJanbonGGhigoJM 2004 Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryot Cell 3 536 545

52. NobileCJNettJEHerndayADHomannORDeneaultJS 2009 Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol 7 e1000133

53. UsmaniSZBonaRLiZ 2009 17 AAG for HSP90 inhibition in cancer–from bench to bedside. Curr Mol Med 9 654 664

54. KimYSAlarconSVLeeSLeeMJGiacconeG 2009 Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9 1479 1492

55. KanekoYOhnoHFukazawaHMurakamiYImamuraY 2010 Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses. Med Mycol 48 606 612

56. TrepelJMollapourMGiacconeGNeckersL 2010 Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10 537 549

57. RichardMLNobileCJBrunoVMMitchellAP 2005 Candida albicans biofilm-defective mutants. Eukaryot Cell 4 1493 1502

58. MowatEButcherJLangSWilliamsCRamageG 2007 Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol 56 1205 1212

59. BurtETDalyRHogansonDTsirulnikovYEssmannM 2003 Isolation and partial characterization of Hsp90 from Candida albicans. Ann Clin Lab Sci 33 86 93

60. OdabasiZMattiuzziGEsteyEKantarjianHSaekiF 2004 Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39 199 205

61. McCourtieJDouglasLJ 1985 Extracellular polymer of Candida albicans: isolation, analysis and role in adhesion. J Gen Microbiol 131 495 503